Graphite Bio Performance
| GRPHDelisted Stock | USD 2.67 0.05 1.84% |
The company retains a Market Volatility (i.e., Beta) of -0.21, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Graphite Bio are expected to decrease at a much lower rate. During the bear market, Graphite Bio is likely to outperform the market. Graphite Bio right now retains a risk of 0.0%. Please check out Graphite Bio potential upside, and the relationship between the jensen alpha and rate of daily change , to decide if Graphite Bio will be following its current trending patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Graphite Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Graphite Bio is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
| Begin Period Cash Flow | 47.7 M |
Graphite |
Graphite Bio Relative Risk vs. Return Landscape
If you would invest 267.00 in Graphite Bio on September 17, 2024 and sell it today you would earn a total of 0.00 from holding Graphite Bio or generate 0.0% return on investment over 90 days. Graphite Bio is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Graphite, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Graphite Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Graphite Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Graphite Bio, and traders can use it to determine the average amount a Graphite Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| GRPH |
Based on monthly moving average Graphite Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Graphite Bio by adding Graphite Bio to a well-diversified portfolio.
Graphite Bio Fundamentals Growth
Graphite Stock prices reflect investors' perceptions of the future prospects and financial health of Graphite Bio, and Graphite Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Graphite Stock performance.
| Return On Equity | -0.52 | |||
| Return On Asset | -0.18 | |||
| Current Valuation | 1.88 M | |||
| Shares Outstanding | 58.24 M | |||
| Price To Earning | 0.70 X | |||
| Price To Book | 1.01 X | |||
| EBITDA | (70.7 M) | |||
| Cash And Equivalents | 322.29 M | |||
| Cash Per Share | 5.54 X | |||
| Total Debt | 362 K | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 3.17 X | |||
| Cash Flow From Operations | (90.01 M) | |||
| Earnings Per Share | (2.19) X | |||
| Total Asset | 188.46 M | |||
| Retained Earnings | (367.05 M) | |||
| Current Asset | 8 K | |||
| Current Liabilities | 451 K | |||
About Graphite Bio Performance
By evaluating Graphite Bio's fundamental ratios, stakeholders can gain valuable insights into Graphite Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Graphite Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Graphite Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. Graphite Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 111 people.Things to note about Graphite Bio performance evaluation
Checking the ongoing alerts about Graphite Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Graphite Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Graphite Bio is now traded under the symbol LENZ. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Graphite Bio is not yet fully synchronised with the market data | |
| Graphite Bio has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (124.65 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Graphite Bio currently holds about 322.29 M in cash with (90.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.54, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 84.0% of the company shares are owned by institutional investors |
- Analyzing Graphite Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Graphite Bio's stock is overvalued or undervalued compared to its peers.
- Examining Graphite Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Graphite Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Graphite Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Graphite Bio's stock. These opinions can provide insight into Graphite Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Graphite Stock
If you are still planning to invest in Graphite Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Graphite Bio's history and understand the potential risks before investing.
| Stocks Directory Find actively traded stocks across global markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |